HONG KONG, January 20, 2026 /PRNewswire/ — AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 19 that it has developed an optimized and improved version of its 20-valent iterative pneumococcal conjugate vaccine, which recently received clinical trial approval from the National Medical Products Administration. This marks a further enrichment and improvement of AIM’s research and development pipeline in the field of pneumococcal vaccine.
Pneumococcal diseases are among the diseases designated as “high priority” for vaccine prevention by the World Health Organization (WHO), which can cause serious consequences such as pneumonia, meningitis and sepsis, particularly threatening children, the elderly and immunocompromised people. AIM’s clinically approved 20-valent pneumococcal conjugate vaccine adds 7 epidemic serotypes to the 13 serotypes covered by the 13-valent vaccine, intended for inoculation in individuals aged 2 months (minimum 6 weeks) and older to prevent infectious diseases caused by the 20 pneumococcal serotypes covered by the product, providing more comprehensive protection to a broader population.
High-efficacy pneumococcal vaccines are hotly contested, but high-end products remain limited. The technical hurdles for multivalent pneumococcal conjugate vaccines are high and the difficulty increases significantly with each additional valence.
Considering the market demand and R&D cycle, AIM has prepared a staged pipeline of iterative products, pushing mature generations into the market while developing new ones. This includes the development of the optimized 20-valent pneumococcal conjugate vaccine and the 24-valent pneumococcal conjugate vaccine based on the 13-valent vaccine, positioning them with differentiated market strategies for different product generations. In addition, the company announced last year that the 23-valent pneumococcal polysaccharide vaccine has completed phase III clinical serological testing and is close to unblinding. With the conjugate vaccine, it will build a complete protection system against pneumococcus throughout the life cycle, meeting various market demands.
Currently, no similar vaccine products are approved for sale in China. AccorAccording to a research report from Fosun International Securities, the 20-valent pneumococcal conjugate vaccine, with its broad-spectrum protective benefit covering 20 pneumococcal serotypes, is expected to become a leading product in the market. As an improved iterative product of the 13-valent pneumococcal conjugate vaccine, the development of the 20-valent pneumococcal conjugate vaccine relies entirely on the Company’s existing mature distribution network to ensure rapid market penetration. Simultaneously, the 20-valent pneumococcal conjugate vaccine covers both pediatric and adult markets, strengthening AIM Vaccine’s competitive advantage in the industry.
SOURCE PURPOSE Vaccine
